Effects of rotation of topical vitamin D3 in chronic plaque-type psoriasis

Journal of Dermatology

Volumn 39, Issue 3, 2012, Pages 275-277

  Imafuku, Shinichi ^a   Kubota, Yumiko ^a   Ito, Kotaro ^a   Koga, Monji ^a   Takahashi, Akira ^a   Nakayama, Juichiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; BON ALFA; CALCIPOTRIOL; CORTICOSTEROID; STEROID; TACALCITOL; UNCLASSIFIED DRUG;

ADULT; AGED; BODY SURFACE; CHRONIC DISEASE; COMORBIDITY; DRUG EFFECT; DRUG SUBSTITUTION; ERYTHEMA; FEMALE; HUMAN; INFORMED CONSENT; LETTER; MAJOR CLINICAL STUDY; MALE; PRURITUS; PSORIASIS; QUESTIONNAIRE; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; CALCITRIOL; CHOLECALCIFEROL; DERMATOLOGIC AGENTS; DIHYDROXYCHOLECALCIFEROLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 84857656861     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01422.x     Document Type: Letter

References (14)

1. Mason J, Mason AR, Cork MJ,. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002; 146: 351-364. (Pubitemid 34603806)
2. MC903 study group. Clinical evaluation of MC903 (Calcipotriol) ointment in patients with psoriasis vulgaris-a right to left comparative study against betamethasone valerate ointment (phase III study). J Clin Ther Med 1995; 12: 2573-2587.
3. High-concentration TV-02 ointment clinical study group. Efficacy and safety of high-concentration TV-02 ointment in patients with psoriasis vulgaris-a double-blind, right-to-left comparative study (phase III study). Nishinihon J Dermatol 2002; 64: 105-119.
4. OCT ointment study group. Phase III study of OCT (22-oxacalcitriol) ointment in patients with psoriasis vulgaris-a double-blind, right-to-left comparative study. Igaku no Ayumi 2000; 194: 887-904.
5. Abe M, Syuto T, Ishibuchi H, Sogabe Y, Yokoyama Y, Ishikawa O,. Efficacy of high-concentration tacalcitol ointment in psoriasis vulgaris after changing from other high-concentration vitamin D3 ointments. Dermatol Online J 2008; 14 (2): 2.
6. Cullen SI,. Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group. South Med J 1996; 89: 1053-1056. (Pubitemid 26376489)
7. Kragballe K, Fogh K, Søgaard H,. Long-term efficacy and tolerability of topical calcipotriol in psoriasis. Results of an open study. Acta Derm Venereol 1991; 71: 475-478.
8. Ramsay CA, Berth-Jones J, Brundin G, et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994; 189: 260-264. (Pubitemid 24249641)
9. Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 2008; 59: 1009-1016.
10. Mild-to-Moderate Psoriasis, 2nd edn, Koo JYM, Lee CS, Lebwohl MG, eds. Informa Healthcare, New York
11. Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer AB, Clark AR,. The physical, psychological and social impact of psoriasis. J Health Psychol 1997; 2: 525-537. (Pubitemid 27475070)
12. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996; 35: 268-269.
13. Singh S, Reddy DC, Pandey SS,. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. J Am Acad Dermatol 2000; 43 (1 Pt 1): 61-65. (Pubitemid 30439714)
14. Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R,. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007; 57 (1): 81-83. (Pubitemid 46908856)